ORENITRAM
Total Payments
$16.7M
Transactions
30,212
Doctors
6,119
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $229,908 | 1,003 | 528 |
| 2023 | $137,302 | 563 | 395 |
| 2022 | $828,758 | 1,994 | 997 |
| 2021 | $1.2M | 4,757 | 1,859 |
| 2020 | $2.7M | 2,967 | 962 |
| 2019 | $5.5M | 6,487 | 1,872 |
| 2018 | $3.0M | 5,303 | 1,950 |
| 2017 | $3.0M | 7,138 | 2,443 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.9M | 3,886 | 77.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 2,123 | 13.6% |
| Food and Beverage | $722,658 | 20,748 | 4.3% |
| Consulting Fee | $490,437 | 192 | 2.9% |
| Travel and Lodging | $227,267 | 818 | 1.4% |
| Education | $13,261 | 2,445 | 0.1% |
Payments by Type
Research
$12.9M
3,886 transactions
General
$3.7M
26,326 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | United Therapeutics Corporation | $2.5M | 22 |
| AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301 | United Therapeutics Corporation | $1.3M | 15 |
| STUDY OF ORAL TREPROSTINL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | United Therapeutics Corporation | $1.2M | 0 |
| OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION- A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310 | United Therapeutics Corporation | $1.1M | 0 |
| ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | United Therapeutics Corporation | $990,062 | 11 |
| EXPEDITE: A 16-WEEK MULTICENTER OPEN-LABEL STUDY OF REMODULIN INDUCTION FOLLOWED BY ORENITRAM OPTIMIZATION IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $985,373 | 1 |
| A PHASE III INTERNATIONAL MULTI-CENTER RANDOMIZED DOUBLE- BLIND PLACEBO-CONTROLLED CLINICAL WORSENING STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING BACKGROUND ORAL MONOTHERAPY | United Therapeutics Corporation | $757,631 | 1 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | United Therapeutics Corporation | $695,340 | 0 |
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE IIIII STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | United Therapeutics Corporation | $672,388 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | United Therapeutics Corporation | $397,644 | 0 |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | United Therapeutics Corporation | $330,899 | 0 |
| TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM-EV | United Therapeutics Corporation | $292,655 | 0 |
| SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL TREPROSTINIL IN PEDIATRIC PAH PATIENTS AGED 7 TO 17 YEARS | United Therapeutics Corporation | $266,990 | 0 |
| ADA - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | United Therapeutics Corporation | $228,828 | 0 |
| AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301 | United Therapeutics Corporation | $224,152 | 0 |
| UNSPECIFIED RESEARCH PROJECTS | United Therapeutics Corporation | $206,935 | 1 |
| STUDY TO COMPARE TRIPLE THERAPY ORAL TREPROSTINIL, AMBRISENTAN, AND TADALAFIL WITH DUAL THERAPY AMBRISENTAN, TADALAFIL, AND PLACEBO IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $148,804 | 0 |
| AN OPEN-LABEL, LONG-TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $86,666 | 0 |
| A PHASE I STUDY OF I-MIBG WITH DINUTUXIMAB FOR RELAPSEDREFRACTORY NEUROBLASTOMA | United Therapeutics Corporation | $86,552 | 0 |
| POLYAMINE DEPLETION BY DFMO TO REDUCE ALLODYNIA AND IMPROVE EFFICACY OF DINUTUXIMAB THERAPY | United Therapeutics Corporation | $82,773 | 0 |
Top Doctors Receiving Payments for ORENITRAM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Bruce Brundage | — | Bend, OR | $12.8M | 3,583 |
| , M.D | Cardiovascular Disease | Columbus, GA | $176,568 | 207 |
| , M.D | Pulmonary Disease | Weston, FL | $164,828 | 328 |
| Gregory Ahearn | — | Phoenix, AZ | $87,003 | 115 |
| , D.O | Pulmonary Disease | Pueblo, CO | $77,906 | 124 |
| , MD | Internal Medicine | Albuquerque, NM | $77,005 | 114 |
| Mark Rumbak | — | Tampa, FL | $75,720 | 93 |
| , D.O | Internal Medicine | Lima, OH | $71,441 | 113 |
| , MD,FACC | Cardiovascular Disease | Oak Lawn, IL | $69,679 | 88 |
| , D.O | Critical Care Medicine | Columbus, OH | $68,342 | 115 |
| , MD | Internal Medicine | Anderson, SC | $65,527 | 81 |
| , M.D | Cardiovascular Disease | Torrance, CA | $65,120 | 81 |
| , M.D | Internal Medicine | Tampa, FL | $63,206 | 74 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $60,022 | 68 |
| , MD | Pulmonary Disease | Austell, GA | $59,360 | 122 |
| , MD | Cardiovascular Disease | Washington, DC | $55,530 | 82 |
| , D.O | General Practice | Durham, NC | $51,079 | 18 |
| , MD | Pulmonary Disease | Guaynabo, PR | $50,491 | 81 |
| , M.D | Internal Medicine | Houston, TX | $49,031 | 98 |
| , MD | Internal Medicine | Houston, TX | $47,701 | 72 |
| , M.D | Pulmonary Disease | Jacksonville, FL | $42,378 | 60 |
| , M.D | Pulmonary Disease | Hauppauge, NY | $42,281 | 78 |
| , MD | Student in an Organized Health Care Education/Training Program | Houston, TX | $41,474 | 88 |
| , MD | Cardiovascular Disease | South Miami, FL | $39,759 | 70 |
| , MD | Internal Medicine | Indianapolis, IN | $38,971 | 60 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $16.7M
- Total Doctors 6,119
- Transactions 30,212
About ORENITRAM
ORENITRAM is a drug associated with $16.7M in payments to 6,119 healthcare providers, recorded across 30,212 transactions in the CMS Open Payments database. The primary manufacturer is United Therapeutics Corporation.
Payment data is available from 2017 to 2024. In 2024, $229,908 was paid across 1,003 transactions to 528 doctors.
The most common payment nature for ORENITRAM is "Unspecified" ($12.9M, 77.6% of total).
ORENITRAM is associated with 20 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF" ($2.5M).